Maraviroc use while Breastfeeding

Summary of Use during Lactation

Minimal information is available on the use of maraviroc during breastfeeding. An alternate agent may be preferred. Achieving and maintaining viral suppression with antiretroviral therapy decreases breastfeeding transmission risk to less than 1%, but not zero. Individuals with HIV who are on antiretroviral therapy with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision. If a viral load is not suppressed, banked pasteurized donor milk or formula is recommended.[1,2]

Drug Levels

Maternal Levels. A woman with HIV was treated with maraviroc 150 mg twice daily, lamivudine 150 mg twice daily and lopinavir 400 mg plus ritonavir 100 mg twice daily. She exclusively breastfed her infant until 6 months of age, then partially breastfed her infant until 7 months of age. At 5 months postpartum, paired maternal milk and plasma samples were obtained before a dose and at 1, 2, 4, 6, 8, and 12 hours after a dose of maraviroc. A peak milk level of 415 mcg/L occurred 2 hours after the dose. The level was almost as high at 4 hours, and then fell to less than 100 mcg/L at 12 hours after the dose. The average milk concentration was 193 mcg/L, which yields a daily infant dose of 29 mcg/kg of maraviroc. Assuming a maternal weight of 60 kg, this translates to a weight-adjusted infant dosage of 0.6%.[3]

Infant Levels. A woman with HIV was treated with maraviroc 150 mg twice daily, lamivudine 150mg twice daily and lopinavir 400 mg plus ritonavir 100 mg twice daily. At 5.5 months of age, a single plasma sample was obtained (time with respect to dose and nursing not stated) from the infant during exclusive breastfeeding. Maraviroc was undetectable (<2.5 mcg/L) in the infant’s plasma.[3]

Effects in Breastfed Infants

A woman with HIV was treated with maraviroc 150 mg twice daily, lamivudine 150mg twice daily and lopinavir 400 mg plus ritonavir 100 mg twice daily. Her infant received zidovudine 4 mg/kg twice daily for 14 days at birth and was exclusively breastfed until 6 months of age, then partially breastfed until 7 months of age. Clinical and laboratory assessment at 2, 4, and 8 weeks, and 3, 6, 9, and 12 months after birth showed normal development. Full blood cell count, renal, and liver parameters remained within normal range. HIV-DNA PCR results were consistently negative, and at 12 months of age, an HIV antibody test was negative.[3]

Effects on Lactation and Breastmilk

Gynecomastia has been reported among men receiving highly active antiretroviral therapy. Gynecomastia is unilateral initially, but progresses to bilateral in about half of cases. No alterations in serum prolactin were noted and spontaneous resolution usually occurred within one year, even with continuation of the regimen.[4-6] Some case reports and in vitro studies have suggested that protease inhibitors might cause hyperprolactinemia and galactorrhea in some male patients,[7,8] although this has been disputed.[9] The relevance of these findings to nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1.

World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. 2021. https://www​.who.int/publications​/i/item/9789240031593 [PubMed: 34370423]

2.

Department of Health and Human Services. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. 2024. https:​//clinicalinfo​.hiv.gov/sites/default​/files/guidelines/documents​/perinatal-hiv​/guidelines-perinatal.pdf

3.

Feiterna-Sperling C, Kruger R, Amara A, et al. Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman. Aids 2019;33:2443-4. [PMC free article: PMC6882546] [PubMed: 31764111]

4.

García-Benayas T, Blanco F, Martin-Carbonero L, et al. Gynecomastia in HIV-infected patients receiving antiretroviral therapy. AIDS Res Hum Retroviruses 2003;19:739-41. [PubMed: 14585204]

5.

Pantanowitz L, Evans D, Gross PD, et al. HIV-related gynecomastia. Breast J 2003;9:131-2. [PubMed: 12603389]

6.

Evans DL, Pantanowitz L, Dezube BJ, et al. Breast enlargement in 13 men who were seropositive for human immunodeficiency virus. Clin Infect Dis 2002;35:1113-9. [PubMed: 12384846]

7.

Hutchinson J, Murphy M, Harries R, et al. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet 2000;356:1003-4. [PubMed: 11041407]

8.

Orlando G, Brunetti L, Vacca M. Ritonavir and saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro. Int J Immunopathol Pharmacol 2002;15:65-8. [PubMed: 12593790]

9.

Montero A, Bottasso OA, Luraghi MR, et al. Galactorrhoea, hyperprolactinaemia, and protease inhibitors. Lancet 2001;357:473-5. [PubMed: 11273087]

Substance Name

Maraviroc

CAS Registry Number

376348-65-1

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Infective Agents

Antiviral Agents

Anti-HIV Agents

Anti-Retroviral Agents

HIV Fusion Inhibitors